ADUS vs ENSG vs HUM Stock Comparison

Addus HomeCare, Ensign and Humana Prices as of Oct 28, 2026 Peers: Industry group
1 more company in this comparison (CHE) Create a free account to keep reading and compare up to 10 companies.
ADUS Addus HomeCare Corp
$122.18 +9.2% 1M +1.4% 1Y
Market cap
$2.28B
P/E
21.2x
Revenue (TTM)
$1.48B
Div. yield
–
Home Health and Senior Care Healthcare
5 wins
ENSG Ensign Group, Inc
$184.11 +4.4% 1M -0.8% 1Y
Market cap
$10.74B
P/E
26.7x
Revenue (TTM)
$5.67B
Div. yield
0.15%
Home Health and Senior Care Healthcare
2 wins
HUM Humana Inc
$411.98 +5.8% 1M +39.7% 1Y
Market cap
$49.47B
P/E
38.7x
Revenue (TTM)
$145.68B
Div. yield
0.65%
Managed Care Healthcare
5 wins

Head to Head

12 decided of 12

Humana leads on 5 of the 12 questions below (Humana 5, Addus HomeCare 5, Ensign 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionADUSENSGHUMLeader
Larger companyMarket capitalisation $2.28B $10.74B $49.47B HUM
Cheaper on earningsLower P/E, profitable companies only 21.2x 26.7x 38.7x ADUS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.0x 22.2x 47.6x ADUS
Faster revenue growthRevenue growth, trailing twelve months +15.9% +17.5% +18.3% HUM
More profitableNet margin, trailing twelve months 7.1% 7.0% 0.9% ADUS
Better return on capitalReturn on invested capital 9.2% 14.3% 6.7% ENSG
Less leveragedLower net debt / EBITDA -0.2x -0.3x -2.7x HUM
Higher dividend yieldTrailing dividend yield — 0.15% 0.65% HUM
Better 1-year returnPrice return, last 12 months +1.4% -0.8% +39.7% HUM
Better 5-year returnAnnualised price return, 5 years +5.5%/yr +18.8%/yr -2.3%/yr ENSG
Less volatileAnnualised volatility, 1 year 29.2% 29.3% 48.1% ADUS
Higher overall scoreMean of the five percentile scores vs peers 69/100 64/100 42/100 ADUS

Percentile Scorecard

ADUSENSGHUM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisADUSENSGHUM
Valuation 87 #13 of 92 69 #29 of 92 54 #12 of 25
Growth 61 #35 of 87 63 #33 of 87 13 #21 of 24
Profitability 73 #24 of 86 75 #22 of 86 44 #14 of 24
Financial Health 87 #14 of 97 72 #28 of 97 68 #9 of 26
Shareholder Returns 41 #33 of 55 43 #32 of 55 33 #11 of 16
Overall 69 64 42
  • ADUS ranked among 102 companies in Healthcare Providers
  • ENSG ranked among 102 companies in Healthcare Providers
  • HUM ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodADUSENSGHUMSPY
1 month +9.2%+4.4%+5.8% +0.9%
3 months +2.6%+1.2%+12.6% +5.9%
6 months +26.0%-1.2%+69.5% +8.5%
Year to date +13.8%+5.7%+60.8% +13.3%
1 year +1.4%-0.8%+39.7% +12.4%
3 years +49.1%+89.2%-19.2% +88.1%
3 years, per year +14.3%+23.7%-6.9% +23.5%
5 years +30.7%+136.0%-11.1% +68.2%
5 years, per year +5.5%+18.8%-2.3% +11.0%
10 years +389.5%+980.5%+140.8% +263.4%
10 years, per year +17.2%+26.9%+9.2% +13.8%

Risk

MeasureADUSENSGHUMSPY
Volatility, 1Y 29.2%29.3%48.1% 12.7%
Downside volatility, 1Y 30.9%24.9%52.4% 12.7%
Beta vs S&P 500, 1Y 0.18-0.060.57 1.00
Return / volatility, 1Y 0.05-0.030.83 0.98
Max drawdown, 5Y -34.9%-31.8%-70.9% -25.4%
From 52-week high -0.5%-14.7%-5.0% -0.9%
52-week high $122.75$215.83$433.45 $779.14
52-week low $88.49$147.13$163.67 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleADUSENSGHUM
P/E now vs peer median 21.2xmedian 25.6x 26.7xmedian 25.6x 38.7xmedian 23.9x
P/S now vs peer median 1.5xmedian 1.6x 1.9xmedian 1.6x 0.3xmedian 0.3x
EV/EBITDA now vs peer median 13.5xmedian 16.3x 16.7xmedian 16.3x 11.5xmedian 12.7x
P/FCF now vs peer median 14.7xmedian 21.3x 21.1xmedian 21.3x 25.4xmedian 15.4x
P/B now vs peer median 2.0xmedian 3.3x 4.2xmedian 3.3x 2.6xmedian 2.5x
PEG now vs peer median 1.07median 0.68 1.68median 0.68 -1.44median 1.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsADUSENSGHUM
Revenue $1.48B $5.67B $145.68B
Gross profit $477.75M $1.20B $19.89B
Operating income $148.23M $509.16M $2.71B
Net income $105.31M $399.32M $1.29B
Free cash flow $154.77M $509.91M $1.95B
EPS (diluted) $5.70 $6.73 $10.56
Cash & equivalents $99.57M $337.59M $6.89B
Total debt $61.60M $198.72M $54.48B
Shares (diluted) 18.47M 59.30M 121.14M
Enterprise value $1.90B $8.87B -$38.33B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricADUSENSGHUM
P/E 21.2x 26.7x 38.7x
P/FCF 14.7x 21.1x 25.4x
P/Operating cash flow 14.0x 15.4x 19.5x
P/S 1.5x 1.9x 0.3x
P/B 2.0x 4.2x 2.6x
P/Tangible book 2.2x 4.2x 2.6x
EV/EBITDA 13.5x 16.7x 11.5x
EV/EBIT 15.1x 20.7x 14.9x
EV/Revenue 1.5x 1.9x 0.3x
EV/FCF 14.5x 20.7x 20.6x
EV/Operating cash flow 13.8x 15.2x 15.8x
PEG (3Y EPS CAGR) 1.07 1.68 -1.44

Growth

14 metrics
MetricADUSENSGHUM
Revenue growth (1Y) 15.9% 17.5% 18.3%
Revenue CAGR (3Y) 13.9% 16.8% 13.8%
Gross profit growth (1Y) 15.1% 21.7% 7.5%
Gross profit CAGR (3Y) 14.9% 16.3% 3.6%
Operating income growth (1Y) 27.5% 26.6% -17.9%
Operating income CAGR (3Y) 23.6% 18.3% -15.3%
Net income growth (1Y) 26.9% 21.6% -18.3%
Net income CAGR (3Y) 25.1% 17.2% -27.4%
EPS growth (1Y) 26.0% 20.9% -19.1%
EPS CAGR (3Y) 19.9% 15.9% -26.9%
Operating cash flow growth (1Y) 61.7% 44.5% -13.4%
Operating cash flow CAGR (3Y) 16.4% 26.8% -42.3%
Free cash flow growth (1Y) 65.3% 76.1% -20.1%
Free cash flow CAGR (3Y) 17.9% 29.2% -45.6%

Profitability

14 metrics
MetricADUSENSGHUM
Gross margin 32.4% 21.2% 13.7%
EBITDA margin 11.3% 11.1% 2.4%
Operating margin 10.0% 9.0% 1.9%
Pretax margin 9.5% 9.4% 1.1%
Net margin 7.1% 7.0% 0.9%
FCF margin 10.5% 9.0% 1.3%
Operating cash flow margin 11.0% 12.3% 1.7%
Return on equity 9.3% 16.0% 6.8%
Return on assets 7.3% 6.8% 2.3%
Return on invested capital 9.2% 14.3% 6.7%
Return on capital employed 11.6% 10.4% 8.1%
Asset turnover 1.0x 1.0x 2.6x
Cash conversion (OCF / net income) 1.5x 1.7x 2.0x
Stock comp / revenue 1.2% 1.1% 0.2%

Financial Health

11 metrics
MetricADUSENSGHUM
Debt / assets 4.2% 3.3% 25.5%
Debt / equity 0.1x 0.1x 0.8x
Net debt / EBITDA -0.2x -0.3x -2.7x
Debt / FCF 0.4x 0.4x 7.5x
Liabilities / assets 21.2% 57.3% 66.3%
Equity / assets 78.8% 42.7% 33.7%
Interest coverage 14.9x 62.8x 3.8x
Current ratio 1.7x 1.2x 1.7x
Quick ratio 1.5x 1.1x 1.3x
Cash ratio 0.6x 0.4x 1.0x
Altman Z-score 6.39 3.62 4.60

Shareholder Returns

7 metrics
MetricADUSENSGHUM
Dividend yield – 0.1% 0.6%
Net buyback yield -0.1% 0.2% 0.3%
Shareholder yield -0.1% 0.3% 1.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusADUSENSGHUM
Forward P/E 17.0xFY2026 22.2xFY2026 47.6xFY2026
EPS, next fiscal year $7.20FY2026 $8.29FY2026 $8.65FY2026
EPS growth, next FY +15.6%FY2026 +26.2%FY2026 -49.5%FY2026
EPS growth, the year after +11.1% -1.8% +84.9%
Revenue, next fiscal year $1.57BFY2026 $5.76BFY2026 $166.70BFY2026
Revenue growth, next FY +10.8%FY2026 +13.9%FY2026 +28.6%FY2026
Revenue growth, the year after +6.1% +16.9% +7.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersADUSENSGHUM
Held by institutions 100.0% 89.8% 98.6%
Institutions holding 303 547 927
Change in shares held, QoQ +0.8% -1.2% +2.7%
Institutions buying 162 250 558
Institutions selling 94 213 266
Buyers to sellers 1.72 1.17 2.10

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ADUSENSGHUM
ADUS 1.00 0.35 0.16
ENSG 0.35 1.00 0.07
HUM 0.16 0.07 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ADUS, ENSG and HUM?

Humana (HUM) is the largest by market capitalisation: Addus HomeCare (ADUS) $2.28B, Ensign (ENSG) $10.74B, Humana (HUM) $49.47B.

Which stock is cheaper, ADUS, ENSG and HUM?

Addus HomeCare (ADUS) trades on the lowest price-to-earnings ratio (Addus HomeCare (ADUS) 21.2x, Ensign (ENSG) 26.7x, Humana (HUM) 38.7x). On next year's consensus earnings, Addus HomeCare (ADUS) is cheapest (Addus HomeCare (ADUS) 17.0x, Ensign (ENSG) 22.2x, Humana (HUM) 47.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Humana (HUM) grew revenue fastest over the trailing twelve months: Addus HomeCare (ADUS) +15.9%, Ensign (ENSG) +17.5%, Humana (HUM) +18.3%.

Which company is more profitable?

Addus HomeCare (ADUS) has the highest net margin (Addus HomeCare (ADUS) 7.1%, Ensign (ENSG) 7.0%, Humana (HUM) 0.9%). On return on invested capital, Ensign (ENSG) leads (Addus HomeCare (ADUS) 9.2%, Ensign (ENSG) 14.3%, Humana (HUM) 6.7%).

Which stock has performed better?

Over the past year Humana (HUM) returned the most: Addus HomeCare (ADUS) +1.4%, Ensign (ENSG) -0.8%, Humana (HUM) +39.7%. Over five years, Ensign (ENSG) compounded fastest (Addus HomeCare (ADUS) +5.5%/yr, Ensign (ENSG) +18.8%/yr, Humana (HUM) -2.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Humana (HUM) has the highest dividend yield: Ensign (ENSG) 0.15%, Humana (HUM) 0.65%. Addus HomeCare (ADUS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Addus HomeCare (ADUS) has been the steadiest (Addus HomeCare (ADUS) 29.2%, Ensign (ENSG) 29.3%, Humana (HUM) 48.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ADUS, ENSG and HUM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Humana (HUM) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.